MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that it has entered into a distribution agreement with Medtronic, Inc. and SpinalGraft Technologies, LLC ("SGT"), a wholly-owned subsidiary of Medtronic. Through the agreement, MiMedx will provide its PURION® processed allograft products to Medtronic to be marketed by SGT for spinal applications.
The MiMedx PURION® processed allograft products distributed to Medtronic will be private-labeled. SGT will promote, market and sell the private-labeled allografts to its customers and end-users through-out the United States.
Parker H. Petit, MiMedx Chairman and CEO, said, "This agreement is a significant milestone for MiMedx in expanding our customer base and broadening the breadth of physicians and patients with access to our PURION® processed allografts. By partnering with Medtronic, many additional physicians and patients can be served through the extensive distribution arm and presence that Medtronic has in the spinal surgery market."